Targeting TROP2 in Breast Cancer: How Experts are Integrating TROP2 ADCs into Clinical Practice

Get up to date on approved and emerging TROP-2–targeted antibody–drug conjugates in triple-negative and hormone receptor–positive advanced breast cancer with downloadable slides and an archived webcast from a live workshop developed for the oncology multidisciplinary care team.

Share

Program Content

Activities

TROP-2 ADCs in Breast Cancer
Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 11, 2023

Activities

TROP2 ADCs in Breast Cancer 2023
TROP-2 in Breast Cancer: How to Integrate ADCs Into Clinical Practice
Video
Congratulations: You achieved a completion on 04/09/2022

Released: November 09, 2023

Expires: November 08, 2024

Faculty

cover img faculity

Aditya Bardia, MD, MPH, FASCO

Program Director, Breast Medical Oncology
Assistant Chief (Translational Research), Division of Hematology-Oncology
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Center
Los Angeles, California

cover img faculity

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, Tennessee

cover img faculity

Mabel Mardones, MD

Physician Partner
Rocky Mountain Cancer Centers
Co-Chair 
USON Breast Cancer Pathways Task Force
Executive Committee Member for Breast Cancer Research 
Sarah Cannon Research Institute
Nashville, Tennessee 

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.